Literature DB >> 8355038

S-phase fraction is a prognostic factor in stage I breast carcinoma.

O Stål1, M Dufmats, T Hatschek, J Carstensen, C Klintenberg, L E Rutqvist, L Skoog, S Sullivan, S Wingren, B Nordenskjöld.   

Abstract

PURPOSE AND METHODS: The prognostic significance of cell proliferation, estimated as cytometric S-phase fraction (SPF), was investigated in node-negative breast cancer patients with small tumors (T1, NO). The 219 stage I patients originated from two series and were diagnosed either from 1978 to 1981 or from 1981 to 1985. The tumors were analyzed for estrogen receptors (ERs) by isoelectric focusing and for cellular DNA content by static cytofluorometry or flow cytometry.
RESULTS: A high SPF correlated with the absence of ERs and abnormal DNA content, and was less often found in tumors smaller than 11 mm compared with those with a diameter between 11 and 20 mm. Among the variables age, tumor size, DNA ploidy, ER status, and SPF, only SPF showed a significant association with distant recurrence and breast cancer survival in systemically untreated patients. The relative recurrence rate for patients with an SPF of 10% or greater was three times that for patients with lower SPFs. Estimated 8-year breast cancer survival rates for the same groups were 72% and 91%, respectively.
CONCLUSION: This study suggests that cytometric SPF has prognostic significance in stage I breast carcinoma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8355038     DOI: 10.1200/JCO.1993.11.9.1717

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  8 in total

Review 1.  Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years.

Authors:  Attiqa N Mirza; Nadeem Q Mirza; Georges Vlastos; S Eva Singletary
Journal:  Ann Surg       Date:  2002-01       Impact factor: 12.969

2.  Short-term significance of DNA ploidy and cell proliferation in breast carcinoma: a multivariate analysis of prognostic markers in a series of 308 patients.

Authors:  A E Pinto; S André; J Soares
Journal:  J Clin Pathol       Date:  1999-08       Impact factor: 3.411

3.  Comparison between different cell kinetic variables in human breast cancer.

Authors:  F Barzanti; M Dal Susino; A Volpi; D Amadori; A Riccobon; E Scarpi; L Medri; L Bernardi; S Naldi; M Aldi; M Gaudio; W Zoli
Journal:  Cell Prolif       Date:  2000-04       Impact factor: 6.831

4.  Long term prognostic value of Nottingham histological grade and its components in early (pT1N0M0) breast carcinoma.

Authors:  S Frkovic-Grazio; M Bracko
Journal:  J Clin Pathol       Date:  2002-02       Impact factor: 3.411

5.  Lack of prognostic significance of the monoclonal antibody Ki-S1, a novel marker of proliferative activity, in node-negative breast carcinoma.

Authors:  P Bevilacqua; P Verderio; M Barbareschi; E Bonoldi; P Boracchi; P Dalla Palma; G Gasparini
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

6.  p53 as a prognostic factor in stage I breast cancer. South-East Sweden Breast Cancer Group.

Authors:  M Stenmark-Askmalm; O Stål; K Olsen; B Nordenskjöld
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

7.  S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer.

Authors:  O Stål; L Skoog; L E Rutqvist; J M Carstensen; S Wingren; S Sullivan; A C Andersson; M Dufmats; B Nordenskjöld
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

8.  Comparison of MIB-1 proliferation index with S-phase fraction in human breast carcinomas.

Authors:  P A Ellis; A Makris; S A Burton; J Titley; M G Ormerod; J Salter; T J Powles; I E Smith; M Dowsett
Journal:  Br J Cancer       Date:  1996-03       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.